Figure 2.

The impact of icotinib on the apoptosis and cell cycle of HCC827 cells. (A) An FCM analysis of apoptotic cells using Annexin V/PI. Q1 depicts the cells that were damaged during the experiment (Annexin V-/PI+); Q2 indicates late-stage apoptotic cells and necrotic cells (Annexin V+/PI+); Q3 depicts normal cells (Annexin V-/PI-); Q4 indicates early apoptotic cells (Annexin V+/PI-). (B) The rate of apoptosis of HCC837 cells in the control group was 2.7±0.46%; following treatment with icotinib the apoptosis rate increased to 16.4±0.91%. (C) An FCM analysis of the cell cycle. (D) In the control group, 66.96±1.42% of the cells were in the G₀/G₁ phase, 26.58±2.12% of the cells were in the S phase and 6.46±2.59% of the cells were in the G₂/M phase. With icotinib, 85.11±1.31% of the cells were in G₀/G₁ phase, while 7.37±1.53% of the cells were in S phase and 7.52±1.15% of the cells were in G₂/M phase. The data are presented as the mean ± standard deviation from three independent experiments. *P<0.05, vs. the control. FCM, flow cytometry; PI, propidium iodide; Q, quadrant.